Physician profile
Mark Mattar
NPI 1841401031
$349,106.48
in general payments reported to CMS, 2019-2025
17 companies · $61K in 2025
The $61K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $29K · 2021: $60K · 2022: $42K · 2023: $52K · 2024: $62K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $152K · Consulting Fee: $13K · Travel and Lodging: $5,901 · Food and Beverage: $3,361 · Honoraria: $1,110 · Education: $68.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $151,909.36 |
| Consulting Fee | $12,683.00 |
| Travel and Lodging | $5,900.88 |
| Food and Beverage | $3,361.25 |
| Honoraria | $1,110.00 |
| Education | $68.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $106,916.76 | 2019-2025 | |
| Janssen Biotech, INC. | $73,211.02 | 2019-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $65,777.22 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $32,998.14 | 2020-2025 | Stelara, Tremfya |
| Pfizer INC. | $26,100.54 | 2019-2023 | |
| Lilly USA, LLC | $20,732.40 | 2023-2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $9,202.00 | 2020-2022 | |
| Celltrion USA INC. | $8,068.35 | 2024-2025 | Zymfentra |
| Janssen Global Services, LLC | $4,200.00 | 2021 | |
| Celgene Corporation | $1,569.04 | 2021-2024 | Zeposia |
| Genzyme Corporation | $146.90 | 2025 | |
| Gilead Sciences, INC. | $96.83 | 2019 | |
| Nestle Healthcare Nutrition INC. | $47.25 | 2023 | |
| Boston Scientific Corporation | $28.03 | 2019-2024 | Exalt Model D |
| Sandoz INC. | $12.00 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mattar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.